Insights on the Diabetes Injection Pens Global Market to 2027 - AstraZeneca, Biocon and Novo Nordisk Among Others

DUBLIN, May 11, 2021 /PRNewswire/ -- The "Diabetes Injection Pens - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Diabetes Injection Pens estimated at US$7.2 Billion in the year 2020, is projected to reach a revised size of US$11.3 Billion by 2027, growing at a CAGR of 6.7% over the period 2020-2027.

Type I Diabetes, one of the segments analyzed in the report, is projected to record 6.5% CAGR and reach US$6.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Type II Diabetes segment is readjusted to a revised 6.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $2 Billion, While China is Forecast to Grow at 10.1% CAGR

The Diabetes Injection Pens market in the U.S. is estimated at US$2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2027 trailing a CAGR of 10.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.7% and 6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Select Competitors (Total 43 Featured):

• AstraZeneca PLC
• Becton, Dickinson and Company
• Biocon Ltd.
• Eli Lilly and Company
• Jiangsu Delfu medical device Co., Ltd.
• Novo Nordisk A/S
• Owen Mumford Ltd.
• Wockhardt Ltd.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

• UNITED STATES
• CANADA
• JAPAN
• CHINA
• EUROPE
• FRANCE
• GERMANY
• ITALY
• UNITED KINGDOM
• SPAIN
• RUSSIA
• REST OF EUROPE
• ASIA-PACIFIC
• AUSTRALIA
• INDIA
• SOUTH KOREA
• REST OF ASIA-PACIFIC
• LATIN AMERICA
• ARGENTINA
• BRAZIL
• MEXICO
• REST OF LATIN AMERICA
• MIDDLE EAST
• IRAN
• ISRAEL
• SAUDI ARABIA
• UNITED ARAB EMIRATES
• REST OF MIDDLE EAST
• AFRICA

IV. COMPETITION

• Total Companies Profiled: 43

For more information about this report visit https://www.researchandmarkets.com/r/fz4dcf

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/insights-on-the-diabetes-injection-pens-global-market-to-2027---astrazeneca-biocon-and-novo-nordisk-among-others-301289069.html

SOURCE Research and Markets